AlphAIAlphAI — Financial news for AI agents
zerohedge.comOCT 13 min read$LLY

Lilly's "Incredible Hulk" Obesity Combo Delivers Record 23% Weight Loss In Diabetics

Eli Lilly's experimental combo of eloralintide and Mounjaro showed 23% weight loss in diabetics, per a Phase 2b trial. The highest dose group lost 54 lbs on average. Lilly shares rose 2.6% today. Novo Nordisk faces increased competition in obesity/diabetes treatments.

Original reporting
zerohedge.com
Published Oct 1, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
7/10
AlphAI data visualization · based on zerohedge.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The data positions Lilly ahead of Novo Nordisk in diabetic weight‑loss efficacy, prompting immediate share price reaction.

02

Market read

First disclosure of significant Phase 2b efficacy data for a major diabetes drug candidate.

03

What to watch

Potential regulatory scrutiny and need for Phase 3 titration optimization may delay rollout.

Relevance 7/10Novelty 9/10Timing: pre‑market today

Background

Eli Lilly presented Phase 2b results for its eloralintide‑tirzepatide combo at the EASD meeting.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Phase 2b trial shows 23% weight loss in diabetics, prompting a 2.6% share rise.

Expected impact

likely upward pressure as market prices in the strong weight‑loss results

Evidence & confidence

Data beats expectations and improves Lilly's competitive position versus Novo Nordisk.

Market effects

Sector

Obesity and diabetes therapeutics sector may see increased competition and valuation shifts.

Regional

US biotech and pharma markets react to the data; European markets follow suit.

Global

Global diabetes drug market outlook is affected, influencing peers worldwide.

Counterpoint

What could challenge this read

Safety concerns and high discontinuation rates could dampen long‑term demand for the combo.

Key entities

  • company
    Eli Lilly

    Pharmaceutical company reporting trial results.

  • company
    Novo Nordisk

    Competitor in obesity/diabetes market.

Read at source← All news

Related articles

OCT 1
$LLYMedAI 8/10

Lilly's Foundayo Cuts Predicted 10-Year Diabetes Risk By Up To 57%

Eli Lilly (LLY) reported that Foundayo, a GLP-1 receptor agonist, reduced predicted 10-year type 2 diabetes risk by 45-57% and cardiovascular disease risk by 13-18% in a Phase 3 trial. The study involved 3,127 adults with obesity or overweight. Foundayo is FDA-approved for chronic weight management and is being studied for other metabolic conditions. LLY shares are currently trading at $1,150.94, down 0.70%.

rttnews.com2 min
OCT 1
$MUMed

First Look: Paramount-Warner Bros. Merger, Micron Earnings, Fed

Micron MU reported strong Q4 earnings and guidance, driven by data center revenue growth. Eli Lilly LLY announced positive results in a weight loss trial. Paramount Global PARA and Warner Bros. Discovery WBD merger was approved. Oracle ORCL shares rose on upbeat guidance. Nike NKE, McCormick MKC, and others are set to report earnings today.

gurufocus.com3 min
OCT 1
$LLYMedAI 8/10

Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease | Eli Lilly and Company

Eli Lilly's oral GLP-1 drug, Foundayo (orforglipron), showed significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease in post-hoc analyses of the ATTAIN-1 trial. The 17.2 mg dose reduced diabetes risk by 57% and cardiovascular disease risk by 18% compared to placebo. These findings suggest potential long-term cost savings for patients and healthcare systems, according to the company.

investor.lilly.com2 min
OCT 1
$LLYMedAI 8/10

Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease

Eli Lilly (LLY) reported that its drug Foundayo (orforglipron) showed significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight. Post-hoc analyses of the ATTAIN-1 trial showed a 57% reduction in diabetes risk and an 18% reduction in cardiovascular disease risk at the highest dose (17.2 mg) compared to placebo. The findings were published in Diabetes, Obesity and Metabolism.

prnewswire.com2 min